FTUS
NTLA icon

Flow Traders U.S.’s Intellia Therapeutics NTLA Stock Holding History

Flow Traders U.S.’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,622
Closed -$306K – 924
2020
Q4 		$306K Buy
+5,622
New +$204K 0.02% 486

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flow Traders U.S.'s NTLA Position: Q1 2021 in Review

Flow Traders U.S. sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 5,622 shares — an estimated $306K sold.

Flow Traders U.S. first reported a position in NTLA in Q4 2020 and held it in 1 quarter. The position peaked at $306K in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Flow Traders U.S. reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Flow Traders U.S. sold 5,622 Intellia Therapeutics shares in Q1 2021, an estimated $306K.
  • Flow Traders U.S. first reported a position in Intellia Therapeutics in Q4 2020 and held it in 1 quarter.
  • Flow Traders U.S.'s Intellia Therapeutics position peaked at $306K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Flow Traders U.S.'s 13F filing for Q1 2021, filed 17 May 2021.